5th Binaytara Precision Oncology Summit: Redefining Cancer Treatment with Molecular Targeted Strategies

San Francisco, CA US
October 24, 2025 to October 25, 2025

The 5th Binaytara Precision Oncology Summit is a two-day, CME-accredited national conference bringing together leading experts and oncology professionals to explore cutting-edge developments in precision oncology. With the theme "Redefining Cancer Treatment with Molecular Targeted Strategies," this summit emphasizes the integration of genomics, novel therapies, and emerging technologies into routine cancer care.

The program features a robust mix of didactic lectures, case-based discussions, panel sessions, molecular tumor boards, abstract presentations, and roundtables, all designed to foster clinical insights and multidisciplinary collaboration. An audience response system will be used throughout the event to engage participants in real-time learning and decision-making.

Key topics include:

  • Advances in genomic medicine and biomarker discovery
  • Germline and somatic profiling in treatment planning
  • Pathway-based therapies, liquid biopsy, and non-invasive diagnostics
  • Artificial intelligence in oncology
  • Ethical issues and barriers to adoption of precision strategies
  • Personalized cancer vaccines and immunotherapy

This summit equips participants with the latest scientific knowledge and practical tools to deliver personalized, evidence-based cancer care. Designed for oncologists, hematologists, pathologists, pharmacists, nurse practitioners, and other healthcare professionals, the event provides a unique opportunity to deepen understanding and improve patient outcomes through precision oncology.

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Organizing Committee 

Program Director:

Binay Shah, MD, MHA - Binaytara

Conference Chair:

Mark Pegram, MD - Stanford University 

Organizing Committee:

Millie Das, MD - VA Palo Alto Health Care System & Stanford University

Mamta Parikh, MD, MS - UC Davis Comprehensive Cancer Center

Sachdev Thomas, MD - Kaiser Permanente

Pamela Munster, MD - UCSF

Abstract Committee:

Co-Chair: Marianne Dubard-Gault, MD, MS - Providence Swedish Cancer Institute

Co-Chair: James Ford, MD - Stanford University

Arya Mariam Roy, MD - The Ohio State University

Rajat Thawani, MD - OHSU

Ronan Hsieh, MD - Providence Swedish Cancer Institute

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Apply current advances in genomic profiling, including germline and somatic testing, to guide individualized cancer treatment strategies.
  2. Evaluate and select appropriate molecular-targeted therapies, including pathway-based agents, immunotherapies, and personalized cancer vaccines.
  3. Interpret results from liquid biopsy, next-generation sequencing, and other molecular diagnostics to inform clinical decision-making.
  4. Analyze complex real-world cases presented in molecular tumor boards and implement evidence-based, patient-centered precision oncology approaches.
  5. Identify ethical, technological, and systemic challenges—including the role of AI and healthcare disparities—in the clinical adoption of precision oncology, and propose strategies to overcome them.

You may also be interested in

2025 Seattle Cellular Therapy Summit: Bringing Cellular Therapies to Every Patient, Everywhere

This CME-accredited activity, 2025 Seattle Cellular Therapy Summit, features leading experts who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular
Las Vegas Hematologic Malignancies Symposium

The Las Vegas Hematologic Malignancies Symposium aims to enhance participants’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize outcomes for patients with hematologic malignancies.
Course summary
Available credit: 
  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
Course opens: 
04/01/2025
Course expires: 
12/28/2025
Event starts: 
10/24/2025 - 8:00am PDT
Event ends: 
10/25/2025 - 5:00pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - OCTOBER 24th, 2025

All times listed in Pacific Daylight Time (PDT).

09:00 AM – 10:00 AM  Registration, Breakfast, and Exhibits

10:00 AM – 10:15 AM  Welcome

10:15 AM – 11:00 AM  Plenary Speech - Advances in Genomic Medicine

11:00 AM – 12:00 PM  Session 1: Genomic Profiling in Cancer

Session Chair: James Ford, MD

11:00 AM – 11:20 AM  Keynote Speech: Germ Line Testing in Cancer Treatment: From Sequencing to Clinical Application 

11:20 AM – 12:00 PM  Panel Discussion - Jeffrey N. Weitzel, MD, FACMG

12:00 PM – 01:00 PM  Lunch & Exhibits

01:00 PM – 02:00 PM  Session 2: Pathway-Based Targeted Therapies in Oncology

Session Chair: 

01:00 PM – 01:20 PM  RTK inhibitors in NSCLC - Nathaniel Myall, MD

01:20 PM – 01:40 PM  PI3K Pathway

01:40 PM – 02:00 PM  Ras/Raf in Melanoma - Adil Daud, MD

02:00 PM – 03:00 PM  Session 3: Molecular Tumor Board 1: Interesting and Challenging Cases in Precision Oncology

Session Chair: Mark Pegram, MD

02:00 PM – 02:15 PM  ESR1 Mutation - Milana V. Dolezal, MD, MSci

02:15 PM – 02:30 PM  MTAP Deletion - Shruti R. Patel, MD

02:30 PM – 02:45 PM  KRAS G12C Mutation - Surbhi Singhal, MD

02:45 PM – 03:00 PM  EZH2 Mutation in Follicular Lymphoma

03:00 PM – 03:30 PM  Break & Exhibits

03:30 PM – 04:00 PM  Session 4: Liquid Biopsy and Non-Invasive Testing

Session Chair: Ash A. Alizadeh, MD, PhD

Panelists: Nicholas Mitsiades, MD, PhD

04:00 PM – 04:30 PM  Session 5: Roundtable Discussion: Ethical Challenges in Precision Oncology

Session Chair:

Panelists: 

04:30 PM – 05:15 PM  Session 6: Personalized Cancer Vaccines in Immuno-Oncology

Session Chair:

04:30 PM – 04:45 PM  Development of Personalized Cancer Vaccines and Immunotherapy 

04:45 PM – 05:15 PM  Panel Discussion

05:15 PM – 06:15 PM  Networking, Exhibits, and Reception
 

DAY 2 - OCTOBER 25th, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, and Exhibits 

08:00 AM – 09:15 AM  Session 7: Artificial Intelligence in Precision Oncology

Session Chair:

Panelists: Haruka Itakura, MD, PhD

09:15 AM – 10:15 AM  Session 8: Oral Abstract Presentations

Session Chair: Marianne Dubard-Gault, MD, MS

**This is a non-CME activity**

10:15 AM – 10:45 AM  Break & Exhibits

10:45 AM – 11:15 AM  Binaytara’s Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA

11:15 AM – 12:15 PM  Session 9: Panel Discussion: Practical Challenges and Barriers in Clinical Adoption of Precision Oncology

Session Chair: Christopher Chen, MD

Panelists: Eric Rosen, MD, FSBI; Uzma Waheed, MD

12:15 PM – 01:15 PM  Lunch & Exhibits

01:15 PM – 02:45 PM  Session 10: Molecular Tumor Board 2: Interesting and Challenging Cases in Precision Oncology

Session Chair: Sachdev Thomas, MD

01:15 PM – 01:30 PM  Menin Inhibitor use in AML

01:30 PM – 01:45 PM  IDH Inhibitor case - Tian Yi Zhang MD, PhD

01:45 PM – 02:00 PM  JAK/STAT Inhibitor - William Shomali, MD

02:00 PM – 02:15 PM  BCL2 Inhibitor case

02:15 PM – 02:30 PM  Tumor Agnostic FDA Drug Approvals - Ana I. Velázquez Mañana, MD, MSc, FASCO

02:30 PM – 02:45 PM  Panel Discussion

02:45 PM – 03:00 PM  Break & Exhibits

03:00 PM – 04:00 PM  Session 11: The Future of Precision Oncology: Biomarker Discovery and Validation

Session Chair: 

03:00 PM – 03:30 PM  Keynote Speech

03:30 PM – 04:00 PM  Panel Discussion 

04:00 PM – 04:45 PM  Session 12: Roundtable Discussion: The Future of Precision Oncology

Session Chair:

Panelists: Rajat Thawani, MD; Irene Wapnir, MD

04:45 PM – 05:00 PM  Closing Remarks and Thank You

05:00 PM  Adjourn

InterContinental San Francisco
888 Howard St
San Francisco, CA 94103
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Mark Pegram, MD

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Novartis;.
Speaker/Topic Presenter(s)

Haruka Itakura, MD, PhD

has a financial relationship (Other) with Pfizer;.
Case Presenter(s)

Nathaniel Myall, MD

has a financial relationship (Grant Or Contract) with Genentech;.

Ana Velazquez Manana, MD MSc

has a financial relationship (Independent contractor) with AbbVie, AstraZeneca, BMS, Merus, Janssen, Novocure, Regeneron;.
has a financial relationship (Grant Or Contract) with Janssen, Roche/Genentech;.

Uzma Waheed, MD

has a financial relationship (Independent contractor) with WhiteRabbit ;.
has a financial relationship (Independent contractor) with Merit Medical;.
Planning committee(s)

Ronan Hsieh, MD, MS

has a financial relationship (Travel) with Merck;.
has a financial relationship (Travel) with Medscape;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Financial Support) with Curio Science;.

Rajat Thawani, Assistant Professor of Medicine, Division of Hematology & Oncology, Knight Cancer Institute, OHSU

has a financial relationship (Independent contractor) with Briston Myers Squibb;.
has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with Boehringer Ingelheim;.
has a financial relationship (Independent contractor) with Nuvation Bio;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Jannsen ;.
has a financial relationship (Independent contractor) with Pfizer;.

Sachdev Thomas, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.

If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binaytara.org/SFPrecisionOnc

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.